Maiwei Biotech (688062.SH) and Qilu Pharmaceutical signed a technology licensing agreement for injectable argastine α

Zhitong Finance App News, Maiwei Biotech (688062.SH) announced that the company and its wholly-owned subsidiary Jiangsu Taikang Biopharmaceutical Co., Ltd. (“Taikang Biology”) and Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) signed a “New Drug Project Technical License Agreement” for the marketed products of injectable argastine α (including the trade name Maliprecen®, product code: 8MW0511). According to the license agreement, Maiwei Biotech exclusively licenses Qilu Pharmaceutical's right to develop, produce, improve, use and commercialize licensed products in Greater China. The total down payment and sales milestone reached up to RMB 500 million, including a one-time non-refundable down payment of RMB 380 million; and royalty fees of up to a double-digit percentage of net sales of licensed products.

According to the announcement, injectable argastine α (8MW0511) is an injectable recombinant (yeast-secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein. It is suitable for adult patients with non-myeloid malignant tumors to use this product to reduce the incidence of infections characterized by febrile neutropenia when receiving myelosuppressive anticancer drugs that are likely to cause febrile neutropenia.

The announcement stated that through the signing of this agreement, the company and Qilu Pharmaceutical have established a cooperative relationship in the field of long-term brightening drugs, with the aim of complementing the advantages and sharing of resources between the partners, and achieving mutual benefit and win-win situation by leveraging their respective resources and advantages, which is conducive to the commercialization of the company's products.